Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update

Bojanic, Kristina; Bogojevic, Mirta Sudaric; Vukadin, Sonja; Sikora, Renata; Ivanac, Gordana; Lucic, Nikola Raguz; Smolic, Martina; Tabll, Ashraf A.; Wu, George Y.; Smolic, Robert

doi:10.14218/jcth.2022.00365

J Clin Transl Hepatol

2023

DOI: 10.14218/jcth.2022.00365

|View full text |Cite

Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update

Kristina Bojanic,

Mirta Sudaric Bogojevic,

Sonja Vukadin

et al.

Abstract: Liver biopsy is historically the gold standard for liver fibrosis assessment of chronic hepatitis C patients. However, with the introduction and validation of noninvasive tests (NITs) to evaluate advanced fibrosis, and the direct-acting antiviral agents for treatment of chronic hepatitis C virus (HCV), the role of NITs have become even more complex. There is now need for longitudinal monitoring and elucidation of cutoff values for prediction of liver-related complication after sustained virological response. T… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients

El-Kassas,

Elakel,

Elsharkawy

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The continuous search for simple, noninvasive methods for assessing liver fibrosis remains very important to help risk-stratify and follow-up patients with chronic hepatitis C virus (HCV). This study aimed to evaluate the diagnostic performance and accuracy of six serological noninvasive scores for the assessment of liver fibrosis in comparison to liver histopathology. This retrospective cohort study included data from 19501 patients with chronic HCV infection who had liver biopsies as an HCV treatment prerequisite within the Egyptian national HCV treatment program. Six noninvasive scores (FIB-4, APRI, King’s score, Fibro-Q, fibrosis index, Fibro-α score) were evaluated and compared to liver histopathology data in assessing different stages of liver fibrosis. The diagnostic performance for each score was assessed using the area under the receiver-operating characteristic curve (AUROC). All six noninvasive scores were statistically significant for predicting different stages of liver fibrosis. Four scores (FIB-4, King’s score, APRI, and Fibro Q) had a better diagnostic performance for predicting different fibrosis stages. FIB-4, followed by the King’s score, performs better in identifying patients with advanced fibrosis at cutoffs of 2.01 and 16.7, respectively, with AUROC of 0.71 for both, and in predicting cirrhosis at cutoffs of 2.21 and 17.4, respectively with AUROC 0.82 for both. Using noninvasive scores for fibrosis assessment is very important, especially in limited resource settings, to rapidly stratify patients who need more specialized care.

show abstract

Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients

El-Kassas,

Elakel,

Elsharkawy

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

New markers of fibrosis in hepatitis C: A step towards the Holy Grail?

Dabos

2024

World J Hepatol

View full text Add to dashboard Cite

In the present issue of the World Journal of Hepatology , Ferrassi et al examine the problem of liver fibrosis staging in chronic hepatitis C. They identify novel biomarkers in an effort to predict accurate fibrosis staging with the aid of the metabolome of Hepatitis C patients. Overall I think Ferrassi et al took a different approach in identifying fibrosis biomarkers, by looking at the patients’ metabolome. Their biomarkers clearly separate patients from controls. They can also separate out, patients with minimal fibrosis (F0-F1 stage) and patients with cirrhosis (F4 stage). Obviously, if these biomarkers were to be widely used, tests for all the important metabolites would need to be readily available for use in hospitals or outpatient setting and that may prove difficult and above all, costly. Nevertheless, this step could eventually lead to a metabolomic approach for novel biomarkers of Fibrosis. Obviously, it would need to be validated, but could represent a step towards the Holy Grail of Hepatology.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update

Cited by 2 publications

References 110 publications

Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients

Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients

New markers of fibrosis in hepatitis C: A step towards the Holy Grail?

Contact Info

Product

Resources

About